-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The 2022 American Society of Clinical Oncology Symposium on Genitourinary Oncology (ASCO-GU) will be held from February 17th to 19th local time
Toripalimab, an anti-PD-1 antibody developed by Junshi Bio, has been approved in China for multiple indications, including melanoma, nasopharyngeal carcinoma, and urothelial carcinoma
The POLARIS-03 study is an open-label, multi-center, phase 2 registration clinical study.
The 2-year follow-up survival data released at the ASCO-GU conference this time showed:
As of September 8, 2021 (24 months after the last patient was enrolled), the median overall survival (OS) was 14.
The study detected and analyzed the tumor mutational burden (TMB) of patients with urothelial carcinoma and found that the group of patients with high levels of TMB could achieve higher treatment response rates, longer progression-free survival (PFS) and OS
In the WES test results of 135 patients, it was found that patients with SMARCA4/PBRM1 or tumor suppressor RB1 mutations, or FRFR2/FGFR3 gene mutations or gene fusions, or NECTIN4 genomic alterations were more likely to be treated with toripalimab.
The study concluded that the 2-year follow-up data of the POLARIS-03 study showed that toripalimab has an encouraging clinical effect in patients with metastatic urothelial cancer refractory to chemotherapy, and the median OS of the patients exceeded 1 year, It was 14.
In addition to the POLARIS-03 study, results from a number of studies of toripalimab will also be announced at this conference, including: A neoadjuvant toripalimab treatment trial RJBLC-I2N003 Neoadjuvant therapy with toripalimab in patients with bladder cancer (MIBC) to evaluate the efficacy and safety of this regimen; another update from the RC48-C014 study to evaluate toripal Effect of limumab combined with RC48-ADC (a novel humanized HER2 antibody-drug conjugate) in the treatment of patients with HER2-positive or even negative metastatic urothelial carcinoma
References:
[1] ASCO-GU22 | POLARIS-03 study updated 2-year follow-up survival data, gene analysis results help immune precision therapy.
